DiaSorin offers the oncology line, in RIA format and on LIAISON® systems.
In vitro assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinised human plasma during the follow-up of cancer patients. The test has to be performed on the LIAISON® Analyzer family.
In vitro assay for the quantitative determination of free human prostate-specific antigen (fPSA) in human serum and plasma (EDTA or heparinised). The test has to be performed on the LIAISON® Analyzer family.
In vitro assay for the quantitative determination of human prostate-specific antigen (PSA) in human serum and plasma (heparinised, EDTA) during the follow-up of patients with carcinoma of the prostate. The test has to be performed on the LIAISON® Analyzer family.
In vitro assay for the quantitative determination of the CA 15-3® antigen in human serum as well as EDTA and heparinised plasma during the follow-up of patients with breast carcinoma. The test has to be performed on the LIAISON® Analyzer family.
In vitro assay for the quantitative determination of CA 125 antigen in human serum as well as in EDTA or heparinised human plasma during the follow-up of patients with primary invasive ovarian carcinoma. The test has to be performed on the LIAISON® Analyzer family.
In vitro assay for the quantitative determination of the CA 19-9™ antigen in human serum as well as EDTA or citrated human plasma during the follow-up of patients with gastrointestinal tumours. The test has to be performed on the LIAISON® Analyzer family.
LIAISON® TPA®-M is a quantitative automated chemiluminescence immunoassay for the in vitro determination of tissue polypeptide antigen, TPA®, in human serum used for the management of patients with tumours arising from epithelial cells, e.g. carcinomas of the lung, breast, gastrointestinal tract, and urinary bladder. The test has to be performed on the LIAISON® Analyzer family.
LIAISON® NSE is an in vitro assay for the quantitative determination of neuron-specific enolase (NSE) in human serum and CSF used for the management of patients with suspected or diagnosed neuroblastoma and small cell lung carcinoma. The test has to be performed on the LIAISON® Analyzer family.
LIAISON® S100 is a quantitative automated chemiluminescent immunoassays (CLIA) for the in vitro determination of protein S-100B in human serum and CSF (Cerebrospinal fluid). LIAISON® S100 is intended for use as an aid in the management of patients suffering from malignant melanoma. The test has to be performed on the LIAISON® Analyzer family.
The DiaSorin LIAISON® Calcitonin II-Gen Assay is a one-step sandwich chemiluminescence immunoassay (CLIA) intended for the quantitative determination of calcitonin in human serum. Assay results should be used in conjunction with other clinical and laboratory data to assist in the diagnosis and management of conditions involving an excess or deficiency of calcitonin. The test has to be performed on the LIAISON® Analyzer family.
In vitro assay for the quantitative determination of alpha-fetoprotein (AFP) in human serum as well as in EDTA and heparinised human plasma or amniotic fluid for pregnancy monitoring and during the follow-up of tumour patients. The test has to be performed on the LIAISON® Analyzer family.
In vitro assay for the quantitative determination of human chorionic gonadotropin (hCG and βhCG) in human serum. The test has to be performed on the LIAISON® Analyzer.
In vitro assay for the quantitative determination of ferritin in human serum and plasma. The test has to be performed on the LIAISON® Analyzer family.
A. Serum and Plasma. In vitro assay for the quantitative determination of β2-microglobulin (B2M) in human serum as well as EDTA, citrated, and heparinised human plasma. The test has to be performed on the LIAISON® Analyzer. B. Urine The use of urine samples is also possible. For this purpose 'B2M-U' has to be selected in the Sample Loading Dialogue (instead of 'B2M-S'). Never start 'B2M-U' with serum or plasma samples! The selection of 'B2M-U' increases automatically the sample volume pipetted to 100 μL. The calibrator volumes and other charac. of the reaction remain unaffected, the concentrations are still expressed as mg/L. Integral calibration is always performed by the 'B2M-S' procedure; adaptation of result output for 'B2M-U' occurs automatically, if selected. Spontaneous urine which has been adjusted to pH 6-8 with 0.5 M NaOH solution immediately after collection should be used for the determination within 24 hours; for longer storage the specimens should be frozen at-20 °C. A preliminary upper reference range for β2-Microglobulin in urine obtained by this method has been estimated to 0.3 mg/L on a basis of 127 apparently normal probands (female and male).
The DiaSorin LIAISON® Thymidine Kinase is a quantitative immunoassay for the in vitro determination of Thymidine Kinase (TK) activity in human serum or EDTA plasma. Determination of serum Thymidine Kinase activity is useful for prognosis and monitoring of patients with hematological malignancies. Assay results should be used in conjunction with other clinical and laboratory data to assist in the diagnosis and management of conditions involving hematologic malignancies. The test has to be performed on the LIAISON® Analyzer family. This assay is intended for in vitro diagnostic use.
Cancer is the uncontrolled growth and spread of cells that may affect almost any tissue of the body.
Lung, prostate, breast, colorectal and stomach are the five most common cancers in the world. With more than 10 million people diagnosed with cancer and greater than 6 million cancer related deaths each year, cancer is considered the 2nd most common cause of death in industrialized countries. Tumour markers are biological substances produced by the tumour cells, generally found in very low concentrations in normal individuals, which can be measured in blood and other body fluids. Increased concentrations indicate the presence of a tumour.
An ideal tumour marker should be used for screening, diagnosis and monitoring of disease progression. However, their most important clinical application is monitoring of cancer once it has been detected and diagnosed by other methods. Appreciation of the usefulness of these markers, either individually or in parallel and recommendations of some Scientific Organizations on how they should be used has improved greatly during the past ten years. Careful interpretation of tumour marker results has led to a definite increase in their clinical significance.
